Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

are taking GLP-1 — glucagon-like peptide-1 — receptor agonists, medications that were initially developed and FDA-approved to treat Type 2 diabetes are also being used off-label for weight ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...